[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insmed Inc (INSM)

Insmed Inc (INSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,422,372
  • Shares Outstanding, K 216,752
  • Annual Sales, $ 606,420 K
  • Annual Income, $ -1,277 M
  • EBIT $ -1,145 M
  • EBITDA $ -1,120 M
  • 60-Month Beta 0.79
  • Price/Sales 37.50
  • Price/Cash Flow N/A
  • Price/Book 32.13

Options Overview Details

View History
  • Implied Volatility 59.69% (+4.75%)
  • Historical Volatility 94.13%
  • IV Percentile 88%
  • IV Rank 46.84%
  • IV High 89.51% on 12/17/25
  • IV Low 33.42% on 09/11/25
  • Expected Move (DTE 12) 7.03 (7.46%)
  • Put/Call Vol Ratio 0.54
  • Today's Volume 2,811
  • Volume Avg (30-Day) 5,548
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 102,642
  • Open Int (30-Day) 85,065
  • Expected Range 87.19 to 101.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.76
  • Number of Estimates 9
  • High Estimate $-0.59
  • Low Estimate $-1.06
  • Prior Year $-1.70
  • Growth Rate Est. (year over year) +55.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.81 +1.52%
on 06/05/26
142.58 -33.92%
on 05/06/26
-45.22 (-32.43%)
since 05/05/26
3-Month
92.81 +1.52%
on 06/05/26
166.18 -43.30%
on 04/06/26
-49.35 (-34.37%)
since 03/05/26
52-Week
70.57 +33.51%
on 06/09/25
212.75 -55.71%
on 12/02/25
+21.48 (+29.53%)
since 06/05/25

Most Recent Stories

More News
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J. , June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

INSM : 94.22 (-10.20%)
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

BRIDGEWATER, N.J. , May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

INSM : 94.22 (-10.20%)
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s...

INSM : 94.22 (-10.20%)
S&P Futures Climb With All Eyes on Key U.S. Jobs Report

June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report.

ESM26 : 7,400.50s (-2.64%)
QCOM : 215.94 (-10.98%)
TTD : 19.95 (-5.14%)
DDOG : 234.11 (-3.90%)
IAG.LN : 420.800 (-0.12%)
ZTS : 79.44 (-0.10%)
AKAM : 149.32 (-6.08%)
XYZ : 68.15 (-3.87%)
RKLB : 110.08 (-8.23%)
RHM.D.DX : 1,206.400 (+1.62%)
ARM : 342.93 (-12.84%)
INSM : 94.22 (-10.20%)
Insmed Q1 Earnings Call Highlights

Insmed (NASDAQ:INSM) executives said the company entered 2026 with strong commercial momentum for BRINSUPRI and continued growth for ARIKAYCE, while advancing late-stage development of TPIP across multiple...

INSM : 94.22 (-10.20%)
S&P 500 Reverses After Hitting Record High as Oil Prices Bounce Back

The S&P 500 Index ($SPX ) (SPY ) today is down -0.40%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.28%. Equity markets retreated...

MPC : 262.01 (-1.89%)
APP : 557.20 (-0.30%)
INTU : 296.76 (-1.73%)
CVX : 187.31 (-0.55%)
DDOG : 234.11 (-3.90%)
SLB : 54.87 (-5.41%)
DASH : 156.80 (-2.04%)
$IUXX : 28,957.60 (-4.77%)
ZNU26 : 109-025s (-0.47%)
MSFT : 416.67 (-2.66%)
MKSI : 301.65 (-8.65%)
OXY : 56.93 (-2.97%)
Stocks Mixed Awaiting an Iran Update

The S&P 500 Index ($SPX ) (SPY ) today is down -0.05%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.20%. June E-mini S&P futures (ESM26...

MPC : 262.01 (-1.89%)
INTU : 296.76 (-1.73%)
DDOG : 234.11 (-3.90%)
SLB : 54.87 (-5.41%)
$IUXX : 28,957.60 (-4.77%)
DASH : 156.80 (-2.04%)
ZNU26 : 109-025s (-0.47%)
MSFT : 416.67 (-2.66%)
MKSI : 301.65 (-8.65%)
OXY : 56.93 (-2.97%)
ESM26 : 7,400.50s (-2.64%)
FANG : 192.62 (-5.09%)
Insmed: Q1 Earnings Snapshot

Insmed: Q1 Earnings Snapshot

INSM : 94.22 (-10.20%)
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update

— Total Company Revenues of $306.0 Million for the First Quarter of 2026—

INSM : 94.22 (-10.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas...

See More

Key Turning Points

3rd Resistance Point 114.07
2nd Resistance Point 109.53
1st Resistance Point 101.88
Last Price 94.22
1st Support Level 89.69
2nd Support Level 85.15
3rd Support Level 77.50

See More

52-Week High 212.75
Fibonacci 61.8% 158.44
Fibonacci 50% 141.66
Fibonacci 38.2% 124.88
Last Price 94.22
52-Week Low 70.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.